Share on:
DSM and Cerapedics will partner to develop and manufacture next-generation peptide enhanced bone graft. The strategic partnership aligns DSM’s regenerative materials capabilities with proprietary synthetic small peptide technology developed by Cerapedics.
DSM’s bioceramic platform is a carbonated apatite matrix used in bone graft substitute applications, which will be combined with Cerapedics’ growth factor in this partnership. The partnership will run from concept through commercialization.
Source: DSM Biomedical
RELATED ARTICLES
Norwood Medical Appoints Gregg Olson as VP Sales & Marketing
Mar 27 2024 , Julie A. Vetalice
Tapping into the Promising Potential of AI in Orthopedics
Mar 26 2024 , BONEZONE Editors
4 Benefits of Additive Manufacturing Design in the Orthopedic Market
Mar 25 2024 , Paragon Medical
Materials Solutions for Medical Device Instrumentation
Mar 22 2024 , Carpenter Technology